About this trial
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.
Eligibility criteria
Qualifiers
A histologically confirmed diagnosis of hepatocellular carcinoma
A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma
Received standard diagnostic and staging procedures as per local guidelines
Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment
Disqualifiers
Lack of or inability to provide informed consent
Synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Primary liver cancer other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma
Secondary liver cancer
Trial design
Treatments tested in this trial
- ELUCIDATE